In a recently published preclinical paper [162], RO7297089, a novel bispecific BCMA/CD16A-directed innate cell engager, demonstrated the ability to induce the lysis of BCMA-positive MM cells through multiple mechanisms, including retargeting of NK cell cytotoxicity and the activation of macrophage-mediated phagocytosis. The gene discussed is FCGR3A; the disease is Miyoshi myopathy.